Controlled release of rasagiline mesylate promotes neuroprotection in a rotenone-induced advanced model of Parkinson's disease

International Journal of Pharmaceutics

Volumn 438, Issue 1-2, 2012, Pages 266-278

  Fernandez M ^a,b   Barcia, E ^a   Fernandez Carballido A ^a   Garcia, L ^a   Slowing, K ^a   Negro, S ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF CONCEPCIÓN   (Chile)

Author keywords

Advanced Parkinson's disease; Microspheres; Neuroprotection; Rasagiline mesylate; Rotenone; SKN AS

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; DNA; MANGANESE SUPEROXIDE DISMUTASE; MICROSPHERE; POLYGLACTIN; PROTEIN BAX; PROTEIN BCL 2; RASAGILINE; REACTIVE OXYGEN METABOLITE; ROTENONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BEHAVIOR CHANGE; CELL VIABILITY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG INDUCED DISEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MICROENCAPSULATION; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; APOPTOSIS; BEHAVIOR, ANIMAL; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; HUMANS; INDANS; LACTIC ACID; MALE; MICROSPHERES; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; POLYGLYCOLIC ACID; RATS; RATS, WISTAR; ROTENONE;

EID: 84867396417     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.09.024     Document Type: Article

References (59)

1. R.B. Banati, S.E. Daniel, and S.B. Blunt Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease Mov. Disord. 13 1998 221 227
2. R. Betarbet, T.B. Sherer, G. MacKenzie, M.V. García-Osuna, A. Panov, and J.T. Greenamyre Chronic systemic perticide exposure reproduces features of Parkinson's disease Nat. Neurosci. 3 2000 1301 1306
3. R. Betarbet, R.M. Canet-Aviles, T.B. Sherer, P.G. Mastroberardino, C. McLendon, J.H. Kim, S. Lund, H.M. Na, G. Taylor, N.F. Bence, R. Kopito, B.B. Seo, T. Yagi, A. Yagi, G. Klinefelter, M.R. Cookson, and J.T. Greenamyre Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system Neurobiol. Dis. 22 2006 404 420
4. S. Bhaskaran, and S. Suresh Biodegradable microspheres of ketorolac tromethamine for parenteral administration J. Microencapsul. 21 2004 743 750
5. J.J. Chen, D. Swope, and K. Dashtipour Comprehensive review of rasagiline, a second generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease Clin. Ther. 29 2007 1825 1849
6. Y.F. Cheng, G.Q. Zhu, M. Wang, H. Cheng, A. Zhou, N. Wang, N. Fang, X.C. Wang, X.Q. Xiao, Z.W. Chen, and Q.L. Li Involvement of ubiquitin proteasome system in protective mechanisms of Puerarin to MPP(+)-elicited apoptosis Neurosci. Res. 63 2009 52 58
7. M.C. de Rijk, L.J. Launer, K. Berger, M.M. Breteler, J.F. Dartigues, M. Baldereschi, L. Fratiglioni, A. Lobo, J. Martinez-Lage, C. Trenkwalder, and A. Hofman Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group Neurology 54 2000 21 23
8. E. Eruslanov, and S. Kusmartsev Identification of ROS using oxidized DCFDA and flow-cytometry D. Armstrong, Advanced Protocols in Oxidative Stress II, Methods in Molecular Biology 2010 Humana Press New Jersey
9. F.M. Farin, Y. Hitosis, S.E. Hallagan, J. Kushleika, J.S. Woods, P.S. Janssen, T. Smith-Weller, G.M. Franklin, P.D. Swanson, and H. Checkoway Genetic polymorphisms of superoxide dismutase in Parkinson's disease Mov. Disord. 16 2001 705 707
10. H.H. Fernández, and J.J. Chen Monoamine oxidase-B inhibition in the treatment of Parkinson's disease Pharmacotherapeutics 27 2007 1745 1855
11. M. Fernández, E. Barcia, and S. Negro Development and validation of a reverse phase liquid chromatography method for the quantification of rasagiline mesylate in biodegradable PLGA microspheres J. Pharm. Biomed. Anal. 49 2009 1185 1191
12. M. Fernández, S. Negro, K. Slowing, A. Fernández- Carballido, and E. Barcia An effective novel delivery strategy of rasagiline for Parkinson's disease Int. J. Pharm. 31 2011 271 280
13. D.R. Guay Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease Am. J. Geriatr. Pharmacother. 4 2006 330 346
14. R. Haobam, K.M. Sindhu, G. Chandra, and K.P. Mohanakuma Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains Behav. Brain Res. 163 2005 159 167
15. A. Hartley, J.M. Stone, C. Heron, J.M. Cooper, and A.H. Schapira Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease J. Neurochem. 63 1994 1987 1990
16. J. Herrmann, and R. Bodmeier Biodegradable, somatostatin acetate containing microspheres prepared by various aqueous and non-aqueous solvent evaporation methods Eur. J. Pharm. Biopharm. 45 1998 75 82
17. K. Imamura, N. Hishikawa, M. Sawada, T. Nagatsu, M. Yoshida, and Y. Hashizume Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains Acta Neuropathol. 106 2003 518 526
18. K. Imamura, N. Hishikawa, K. Ono, H. Suzuki, M. Sawada, T. Nagatsu, M. Yoshida, and Y. Hashizume Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains Acta Neuropathol. 109 2005 141 150
19. A.C. Jones, Y. Yamamura, L. Almasy, S. Bohlega, B. Elibol, J. Hubble, S. Kuzuhara, M. Uchida, T. Yanagi, D.E. Weeks, and T.G. Nygaard Autosomal recessive juvenile parkinsonism maps to 6q25.2-q27 in four ethnic groups: detailed genetic mapping of the linked region Am. J. Hum. Genet. 63 1998 80 87
20. S.P. Kasturi, H. Qin, K.S. Thomson, S. El-Bereir, S. Cha, S. Neelapu, L.W. Kwak, and L. Roy Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles J. Control. Release 113 2006 261 270
21. A. Koch, K. Lehmann-Horn, J.C. Dächsel, T. Gasser, P.J. Kahle, and C.B. Lücking Proteasomal inhibition reduces parkin mRNA in PC12 and SH-SY5Y cells Parkinsonism Relat. Disord. 15 2009 220 225
22. P.A. LeWitt, and D.C. Taylor Protection against Parkinson's disease progression: clinical experience Neurotherapeutics 5 2008 210 225
23. M. Li, O. Rouaud, and D. Poncelet Microencapsulation by solvent evaporation: state of the art for process engineering approaches Int. J. Pharm. 363 2008 26 39
24. K.J. Livat, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method Methods 25 2001 402 408
25. W. Maruyama, Y. Askao, M.C. Carrillo, K. Kitani, M. Youdim, and M. Naoi Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes Neurotoxicol. Teratol. 24 2002 675 682
26. E.A. Mazzio, R.R. Reams, and K.F. Soliman The role of oxidative stress, impaired glycolisis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro Brain Res. 1004 2004 29 44
27. D.E. Merry, and S.L. Kosrsmeyer Bcl-2 gene family in the nervous system Annu. Rev. Neurosci. 20 1997 245 267
28. P.C. Naha, V. Kanchan, and A.K. Panda Evaluation of parenteral depot insulin formulation using PLGA and PLA microparticles J. Biomater. Appl. 24 2009 309 325
29. M. Naoi, and W. Maruyama Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease Expert Rev. Neurother. 9 2009 1233 1250
30. H. Okada One- and three-month release injectable microspheres of the LH-RH superagonist leuprolin acetate Adv. Drug Deliver. Rev. 28 1997 43 70
31. N. Olea-Herrero, D. Vara, S. Malagarie-Cazenavel, and I. Díaz-Laviada Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R()-Methanandamide and JWH-015: involvement of CB2 Br. J. Cancer 101 2009 940 950
32. Parkinson Study Group A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study Arch. Neurol. 9 2002 1937 1943
33. Parkinson Study Group A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO Study Arch. Neurol. 62 2005 241 248
34. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 2nd ed. 1998 Academic Press Orlando, FL
35. K. Pistel, and T. Kissel Effects of salt addition on the microencapsulation of proteins using W/O/W double emulsion technique J. Microencapsul. 17 2000 467 483
36. O. Rascol, D. Brooks, E. Melamed, W. Oertel, W. Poewe, F. Stocchi, and E. Tolosa LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial Lancet 365 2005 947 954
37. Y. Ren, W. Liu, H. Jiang, Q. Jiang, and J. Feng Selective vulnerability of dopaminergic neurons to microtubule depolymerization J. Biol. Chem. 280 2005 34105 34112
38. P.L. Ritger, and N.A. Peppas A simple equation for description of solute release I. Fickian and non-Fickian release from nom-swellable devices in the form of non-swellable devices in the form of slabs, spheres, cylinders or discs J. Control. Release 5 1987 33 36
39. S. Samantaray, V.H. Knaryan, M.K. Guyton, D.D. Matzelle, S.K. Ray, and N.L. Banik The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis rats Neuroscience 146 2007 741 755
40. M.I. Sánchez-Reus, M.A. Gómez del Rio, I. Iglesias, M. Elorza, K. Slowing, and J. Benedí Standardized Hypericum perforatum reduces oxidative stress and increases gene expression of antioxidant enzymes on rotenone-exposed rats Neuropharmacology 52 2007 606 616
41. H.S. Saravanan, K.M. Sindhu, and K.P. Mohanakumar Intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease Brain Res. 1049 2005 147 155
42. M. Sedelis, R.K. Schwarting, and J.P. Huston Behavioral phenotyping of the MPTP mouse model of Parkinson's disease Behav. Brain Res. 125 2001 109 122
43. J.Y. Seo, A. Masamune, T. Shimosegawa, and H. Kim Protective effect of lycopene on oxidative stress-induced cell death of pancreatic acinar cells Ann. N.Y. Acad. Sci. 1171 2009 570 575
44. T.B. Sherer, P.A. Trimmer, K. Borland, J.K. Parks, J.P. Bennett Jr., and J.B. Tuttle Chronic reduction in complex I function alters calcium signaling in SH-SY5Y neuroblastoma cells Brain Res. 891 2001 94 105
45. T.B. Sherer, R. Betarbet, A.K. Stout, S. Lund, M. Baptista, A.V. Panov, M.R. Cookson, and J.T. Greenamyre An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage J. Neurosci. 22 2002 7006 7015
46. T.B. Sherer, R. Betarberbet, C.M. Tasta, B.B. Seo, J.R. Richardson, J.H. Kim, G.W. Miller, T. Yagi, A.M. Yagi, and J.T. Greenamyre Mechanism of toxicity in rotenone models of Parkinson's disease J. Neurosci. 23 2003 10756 10764
47. K.M. Sindhu, K.S. Saravanan, and K.P. Mohanakumar Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion Brain Res. 1051 2005 25 34
48. J.W. Slot, H.J. Geuze, B.A. Fereman, and J.B. Crapo Intracelullular localization of the copper-zinc and manganese superoxide dismutases in rat liver parenchymal cells Lab. Invest. 55 1986 363 371
49. K. Sudha, A.V. Rao, S. Rao, and A. Rao Free radical toxicity and antioxidants in Parkinon's disease Neurol. India 51 2003 60 62
50. S. Takada, T. Kurokawa, K. Miyazaki, S. Iwasa, and Y. Ogawa Sustained release of a water-soluble GP IIb/IIIa antagonist from copoly(dl-lactic/ glycolic)acid microspheres Int. J. Pharm. 146 1997 147 157
51. H. Takeuchi, T. Yanagida, M. Inden, K. Takata, Y. Kitamura, K. Yamakawa, H. Sawada, Y. Izumi, N. Yamamoto, T. Kihara, K. Uemura, H. Inoue, T. Taniguchi, A. Akaike, R. Takahashi, and S. Shimohama Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models J. Neurosci. Res. 87 2009 576 585
52. D.J. Talpade, J.G. Greene, D.S. Higgins Jr., and J.T. Greenamyre In vivo labelling of mitochondrial complex I (NADH-ubiquinone oxidoreductase) in rat brain using [3H]dihydrorotenone J. Neurochem. 75 2000 2611 2621
53. J.P. Taylor, J. Hardy, and K.H. Fischbeck Toxic proteins in neurodegenerative disease Science 296 2002 1991 1995
54. M. Tompkins, E. Basgall, E. Zamrini, and W.D. Hill Apoptotic-like changes in Lewy body-associated disorders and normal aging in substantia nigral neurons Am. J. Pathol. 150 1997 119 131
55. G. Tórsdóttir, S. Sveinbjörnsdóttir, J. Kristinsson, J. Snaedal, and T. Jóhannesson Ceruloplasmin and superoxide dismutase (SOD1) in Parkinson's disease: a follow-up study J. Neurol. Sci. 24 2006 53 58
56. X.C. Xiao, L.Y. Chu, W.M. Chen, and J.H. Zhu Monodispersed thermoresponsive hydrogel microspheres with a volume phase transition driven by hydrogen bonding Polymer 46 2005 3199 3209
57. M.B.H. Youdim, A. Gross, and J.P.M. Finberg Rasagiline [N-propargyl-1R(p)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B Br. J. Pharmacol. 132 2001 500 506
58. M.B. Youdim, and M. Weinstock Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline Mech. Ageing Dev. 30 2002 1081 1086
59. M.B. Youdim, W. Maruyama, and M. Naoi Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug rasagiline Drugs Today 41 2005 369 391